Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Englisch

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Early Intervention in Psychiatry|May 13, 2016
Early cognitive basic symptoms are accompanied by neurocognitive impairment in patients with an 'at-risk mental state' for psychosisSarah Eisenacher, Franziska Rausch, Fabian Ainser, et al.
Journal of Clinical Psychopharmacology|November 3, 2016
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Pharmacopsychiatry|May 8, 2018
Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Journal of Clinical Psychopharmacology|June 19, 2018
Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Sarah Eisenacher, et al.
European Archives of Psychiatry and Clinical Neuroscience|December 13, 2018
Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapineDaniela Mier, Frederike Schirmbeck, Gabriela Stoessel, et al.
Psychiatry Research|April 18, 2016
Bias against disconfirmatory evidence in the 'at-risk mental state' and during psychosisSarah Eisenacher, Franziska Rausch, Daniela Mier, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 28, 2016
Fast sleep spindle reduction in schizophrenia and healthy first-degree relatives: association with impaired cognitive function and potential intermediate phenotypeClaudia Schilling, Manuel Schlipf, Simone Spietzack, et al.
BMC Psychiatry|February 28, 2016
Investigating the efficacy of an individualized metacognitive therapy program (MCT+) for psychosis: study protocol of a multi-center randomized controlled trialBrooke C Schneider, Martin Brüne, Francesca Bohn, et al.
The Lancet. Psychiatry|March 11, 2022
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trialChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 6, 2019
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and designChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Early Intervention in Psychiatry|May 13, 2016
Early cognitive basic symptoms are accompanied by neurocognitive impairment in patients with an 'at-risk mental state' for psychosisSarah Eisenacher, Franziska Rausch, Fabian Ainser, et al.
Journal of Clinical Psychopharmacology|November 3, 2016
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Pharmacopsychiatry|May 8, 2018
Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Journal of Clinical Psychopharmacology|June 19, 2018
Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Sarah Eisenacher, et al.
European Archives of Psychiatry and Clinical Neuroscience|December 13, 2018
Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapineDaniela Mier, Frederike Schirmbeck, Gabriela Stoessel, et al.
Psychiatry Research|April 18, 2016
Bias against disconfirmatory evidence in the 'at-risk mental state' and during psychosisSarah Eisenacher, Franziska Rausch, Daniela Mier, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 28, 2016
Fast sleep spindle reduction in schizophrenia and healthy first-degree relatives: association with impaired cognitive function and potential intermediate phenotypeClaudia Schilling, Manuel Schlipf, Simone Spietzack, et al.
BMC Psychiatry|February 28, 2016
Investigating the efficacy of an individualized metacognitive therapy program (MCT+) for psychosis: study protocol of a multi-center randomized controlled trialBrooke C Schneider, Martin Brüne, Francesca Bohn, et al.
The Lancet. Psychiatry|March 11, 2022
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trialChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 6, 2019
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and designChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.
Pageof 4